According to the World Health Organization (WHO), there are more than 70 potential vaccines under development, with three already in clinical trials.

The U.S. Food and Drug Administration reviewed several drugs under Priority Review ahead of their PDUFA target action dates scheduled during the week of March 8th, 2020.

The Chinese government is turning to a drug developed by AbbVie for HIV patients as a potential treatment for the coronavirus outbreak that has reached the shores of the United States.

Johnson & Johnson filed for an approval from European regulators for the company’s two-dose experimental vaccine to protect against Ebola.

Regeneron Pharmaceuticals Inc. said the company’s experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death.

GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.

Scientists working on developing vaccines against Ebola have found they can “harvest” antibodies from volunteers vaccinated in research trials and use them to make treatments for the deadly viral infection.

PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.

As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials took four experimental vaccines to the front lines and began to administer it to patients who may have been exposed to the deadly virus.

  Wiley, in partnership with the World Federation of Science Journalists (WFSJ) and Association of Health Care Journalists (AHCJ), is offering an educational webinar series for journalists called Science Talks. These complimentary, one-hour sessions are brought to you by The Wiley Network and provide an on-going training option for journalists. Science Talks with Dr. Peter […]